Brought to you by 
Cardiodyne Inc., Endovasc co-develop liposome heart agents
13 Jul 1999
Executive Summary
Trimedyne's Cardiodyne Inc. division has agreed to co-develop liposome encapsulated agents (i.e., fibroblast and vascular growth factors) in order to treat congestive heart failure, with Endovasc Ltd. Inc.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Liposomes
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cardiodyne Inc., Endovasc co-develop liposome heart agents
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice